'Amgen' CEO Returns Thousands of Shares for Tax Payments While Maintaining Strong Stake

On May 2 and May 7, Robert A. Bradway, chairman and CEO of Amgen Inc. (NASDAQ: AMGN), returned thousands of F-coded shares to the company to cover withholding taxes and related expenses on his equity awards. The May 7 transaction was disclosed at approximately $690,000 (about 900 million KRW).

Despite these two tax-related transactions, Bradway still directly holds roughly 500,000 Amgen shares. When including shares held in a grantor retained annuity trust (GRAT), those registered in his spouse’s name, and dividends attributable to unvested restricted stock units (RSUs), he maintains a significant overall stake in the company.

On May 19, independent director Wanda M. Austin acquired around 600 additional common shares through RSU vesting under the board compensation plan, modestly increasing her personal holdings without any offsetting sales.

Amgen recently announced an additional $300 million (approximately 390 billion KRW) investment in its Puerto Rico manufacturing facility to expand U.S. biopharmaceutical production capacity, bringing its total U.S. manufacturing investments to nearly $2 billion over the past year.

In its Q1 2026 financial results released in late April, the company reaffirmed its full-year guidance based on quarterly revenue growth. Analyst reports have since continued to raise price targets, citing Amgen’s solid performance trajectory.

Headquartered in California, Amgen is a global biotech company that develops and manufactures biologic therapies for cancer, cardiovascular and inflammatory diseases, rare disorders, and obesity-related conditions, supplying these products worldwide. Since its founding in the 1980s, the company has become a leading U.S. pharmaceutical and biotech player, driven by blockbusters such as Repatha and Enbrel and bolstered by its recent acquisition of Horizon Therapeutics’ assets.